BCAX
Bicara Therapeutics Inc. Common Stock
There isn't enough reported data to score BCAX yet.
BCAX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
BCAX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
BCAX PE Valuation
BCAX has no meaningful PE right now: it lost money over the past year.
BCAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect BCAX's losses to grow, with revenue holding steady.
BCAX Earnings Per Share
BCAX lost $3.46 per share over the past year, a bigger loss than the year before.
BCAX Quarterly Revenue
BCAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$56.8M | -$27.5M |
| Q2 2026 | -$44.3M | -$18.7M |
| Q1 2026 | -$37.6M | -$9.5M |
| Q4 2025 | -$24.1M | +$5.9M |
| Q2 2025 | -$25.6M | -$12.7M |
| Q1 2025 | -$28.1M | -$13.5M |
| Q4 2024 | -$30.1M | -$21.6M |
| Q2 2024 | -$12.9M | +$603K |
BCAX has burned cash in almost every quarter: −$163M over the past year, against −$113M the year before.
BCAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +449K shares |
| 1 year | +25% | +13.8M shares |
| 3 years | +25% | +13.8M shares |
BCAX has 68M diluted shares, up 25% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
BCAX Net Leverage
BCAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BCAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.3 | Oversold |
| Stochastic | 6.2 | Oversold |
BCAX's weekly RSI is 27 (oversold) and its Stochastic is 6 (oversold).
BCAX PE vs Healthcare Sector
BCAX has no meaningful PE right now: it lost money over the past year.
BCAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.5 | 30% below |
| 20 week MA | $21.2 | 52% below |
| 50 week MA | $20.1 | 50% below |
| 100 week MA | $16.6 | 39% below |
BCAX is in a downtrend: it's below all four of its weekly moving averages, and 39% below its 100-week average.
BCAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $23.4 | $18.3 | -22% |
| 2025 | $18.3 | $16.8 | -8% |
| 2026 YTD | $16.8 | $10.1 | -40% |
BCAX has finished every year since 2024 lower, and it's down 40% so far in 2026.